Showing 44,521 - 44,540 results of 62,523 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 5 ((step decrease) OR (we decrease)) ))', query time: 1.60s Refine Results
  1. 44521

    Table_7_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  2. 44522

    Table_10_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  3. 44523

    Table_6_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  4. 44524

    Table_3_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  5. 44525

    Table_4_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  6. 44526

    Table_2_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  7. 44527

    Table_1_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  8. 44528

    Table_8_Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease.xlsx by Jerzy K. Kulski (3229236)

    Published 2024
    “…Only the expressed HLA-DRA*01:01:01 and -DQA1*03:01:01 protective alleles (PD v HC), the -DQA1*03:03:01 risk (HC v Prodrome) or protective allele (PD v Prodrome), the -DRA*01:01:02 and -DRB4*01:03:02 risk alleles (SWEDD v HC), and the NR_SVA_381 present genotype (PD v HC) at a 5% homozygous insertion frequency near HLA-DPA1, were significant (Pc<0.1) after Bonferroni corrections. …”
  9. 44529

    Equilibrium conditions for all combinations of <i>μ</i> and <i>e</i> tested here. by L. S. Premo (234955)

    Published 2010
    “…<p>Richness decreases quickly from an initial value of 2500 and cultural diversity reaches equilibrium by the 50,000<sup>th</sup> time step in all populations. …”
  10. 44530

    Improving the measurement of TMS-assessed voluntary activation in the knee extensors by Jeanne Dekerle (800587)

    Published 2019
    “…In a fresh state, potentiated twitch force was unchanged following 1x5C but decreased following 2x5C (<i>P</i><0.05). …”
  11. 44531

    Dietary net energy for gilts from 25 to 100 kg body weight by Danilo Alves Marçal (5837930)

    Published 2018
    “…Corn-soybean meal-based diets were formulated to be fed in three phases (25 to 50, 50 to 70, and 70 to 100 kg BW). Soybean oil was added to replace the inert ingredient kaolin to meet the NE level of each diet. …”
  12. 44532

    FGFR2 is required for growth of NCI-H716 cells. by Anjili Mathur (163690)

    Published 2014
    “…Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. …”
  13. 44533
  14. 44534
  15. 44535
  16. 44536
  17. 44537

    QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells by Neha Laxane (19851759)

    Published 2024
    “…</p> <p><b>Conclusion:</b> Formulated nanoparticles had a low IC<sub>50</sub> value and enhanced cellular uptake.…”
  18. 44538
  19. 44539
  20. 44540

    Stability of an anaerobic single reactor filled with dolomitic limestone with increased organic load of sugarcane by Maria Magdalena Ribas Döll (4680364)

    Published 2017
    “…This bench reactor was filled with dolomitic limestone with a horizontal plug flow to simulate a drainage channel. …”